How well do health systems monitor HIV-associated comorbidities? HIV Outcomes at HIV Drug Therapy Glasgow 2018
News
25 October 2018

How well do health systems monitor HIV-associated comorbidities? HIV Outcomes at HIV Drug Therapy Glasgow 2018

Steering group co-chair Professor Jane Anderson (Consultant Physician, Homerton University Hospital, London) will present findings from HIV Outcomes' assessment of how effectively health systems are monitoring HIV-associated comorbidities at this year's HIV Drug Therapy conference in Glasgow on 28-31 October 2018.

While HIV has become a chronic condition, evidence suggests that there are a growing number of people living with HIV suffering from non-AIDS-defining comorbidities. Using current global and European frameworks, the HIV Outcomes abstract assesses whether existing monitoring frameworks sufficiently enable European countries to observe and understand the comorbidities that impact on the health and well-being of people living with HIV.

The abstract is taken from research work being undertaken by the HIV Outcomes study group.

More updates All

02 April 2020
People living with HIV face discrimination in society and in healthcare systems – following Zero Discrimination Day (1 March), HIV Outcomes draws policy makers' attention to the concrete actions that they can ...
More
News
05 March 2020
We regret to inform you that due to IT technical issues related to the coronavirus outbreak, the webinar planned for tomorrow (17March at 15.00 CET) will be postponed until further notice. ...
More
Report
14 February 2020
With the aim of focusing European thought-leadership on delivering the greatest potential impact at national level, the HIV Outcomes Steering Group ‘road-tested’ the HIV Outcomes recommendations in Germany and Romania ...
More
Filters
Initiative Partners
  • Aids Action Europe
  • AFEW International
  • East Europe and Central Asia Union of PLWH
  • European AIDS Treatment Group
  • Gilead
  • ViiV Healthcare
This initiative is enabled by sponsorship provided by Gilead Sciences and ViiV Healthcare.